Sea Crest Wealth Management, LLC Editas Medicine, Inc. Transaction History

Sea Crest Wealth Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$9.99 - $21.35 $12,477 - $26,666	1,249 New	1,249 $15,000
Q3 2021 Nov 16, 2021	SELL	$39.27 - $72.94 $277,756 - $515,904	-7,073 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $578,051 - $1.05 Million	-18,474 Reduced 72.31%	7,073 $401,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $51,980 - $118,569	1,309 Added 5.4%	25,547 $1.07 Million
Q4 2020 Feb 09, 2021	BUY	$27.07 - $84.35 $656,122 - $2.04 Million	24,238 New	24,238 $1.7 Million
Q3 2020 Nov 12, 2020	SELL	$28.06 - $37.16 $267,327 - $354,023	-9,527 Closed	0 $0
Q2 2020 Jul 27, 2020	BUY	$18.5 - $34.34 $176,249 - $327,157	9,527 New	9,527 $282,000
Q2 2019 Jul 19, 2019	SELL	$20.48 - $27.76 $4,526 - $6,134	-221 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$18.19 - $31.79 $5,457 - $9,537	-300 Reduced 57.58%	221 $5,000
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $23,087 - $32,055	-835 Reduced 61.58%	521 $17,000
Q2 2018 Aug 03, 2018	BUY	$31.4 - $41.01 $42,578 - $55,609	1,356 New	1,356 $49,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Sea Crest Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sea Crest Wealth Management, LLC with notifications on news.